New study tests Nerve-Saving support for bladder cancer patients
NCT ID NCT07629700
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a supportive product called Neuridase can help reduce nerve damage (peripheral neuropathy) caused by a combination of two cancer drugs (enfortumab vedotin and pembrolizumab) in people with advanced bladder cancer. About 40 participants will receive standard treatment plus Neuridase, and researchers will track nerve symptoms and quality of life over time. The goal is to understand how neuropathy develops and whether Neuridase can improve treatment tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Neuridase (a supportive non-drug product)
What this could lead to
If it works, this could point toward a way to manage nerve damage from cancer treatment, helping patients stay on therapy with better quality of life.
What could go wrong
This is a small, early exploratory study with no control group. Neuridase's role is unproven, and the main focus is observation, not a guaranteed benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••